Characterisation of BiologIC’s 3D printed biocomputer platform for advanced therapies, cellular agriculture and diagnostics

BiologIC Technologies正在利用基础知识产权和最新的增材制造（3D打印）技术开发世界上第一台生物计算机。第一代生物计算机正在开发中，用于推进诊断、先进疗法、新疫苗和培养肉类的应用，并旨在为下一代合成生物学提供大规模动力。我们使用3D打印作为生物计算机平台的制造过程。多材料3D打印可以实现材料（聚合物和弹性体）的数字混合，使我们能够生产出一个将流体、电子、光学和流体力学集成到一个系统中的单一系统。将这些系统引入受监管的市场（如先进疗法的制造）的挑战之一是控制材料。BiologIC已经开发了关于3D打印系统在其技术的每一层的生物相容性的专有技术。此前的研究表明，生物技术的后-加工方法可以有效地提高3D打印系统的生物相容性，从而实现分子和细胞生物学应用，尽管需要进一步优化。通过通过该项目与外部专业知识合作，BiologIC将表征进一步开发生物计算机平台所需的3D打印组件，这将实现合成材料生产的范式转变生物学、先进疗法和诊断学。

BiologIC Technologies is developing the first world's biocomputer leveraging foundational IP and the latest additive manufacturing (3D printing) technologies. The first generation of the biocomputer is being developed to advance applications in diagnostics, advanced therapies, new vaccines and cultured meat and is designed to power the next generation of synthetic biology at scale.We use 3D printing as the fabrication process of the biocomputer platform. Multi-material 3D printing enables digital blending of materials (polymers and elastomers) that lets us produce a single system that integrates fluidics, electronics, optics and pneumatics into a single system.One of the challenges in bringing these systems to regulated markets such as manufacturing of advanced therapies is controlling the materials. BiologIC has developed proprietary knowhow regarding biocompatibility of the 3D printed system across each layer of its technology. Previous work has shown that BiologIC's post-processing methodologies can efficiently increase the biocompatibility of the 3D printed systems enabling molecular and cellular biology applications although further optimisation is desirable.By collaborating with external expertise through this project BiologIC will characterise the 3D printed components necessary for the further development of the biocomputer platform that will enable a paradigm shift in the production of synthetic biology, advanced therapies and diagnostics.